1. Scrip
  2. >>Business
  3. >>Financing
  4. >>Finance Watch

Finance Watch: Gilde Closes Sixth Venture Fund With €740m For Drugs, MedTech

Cash For Start-Up And Growth-Stage Companies

 
• By Mandy Jackson

Private Company Edition: The €740m ($806.5m) Gilde Healthcare Venture&Growth VI Fund will back companies in Europe and North America. Among recent financings, VectorY raised a €129m ($138m) series A round, EyeBio expanded its series A to $130m and MBrace raised an $85m series B.

Finance Watch Private Company
• Source: Shutterstock

Gilde Healthcare, a venture capital and private equity firm with more than €2.5bn in invested capital, closed its Gilde Healthcare Venture&Growth VI Fund with €740m ($806.5m) in commitments, building on an initial close in April of €600m ($653.9m).

Even during a period in which fundraising has been difficult for start-ups and growth-stage companies, Gilde noted that it has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Finance Watch

More from Financing

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By Joseph Haas

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.